ArticleBMC infectious diseases2022

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.

Karan Pattni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.